Trial · NCT07910656
PDO Thread Embedding Plus Binh Vi Tablets for Gastroesophageal Reflux Disease
NCT07910656, Not applicable, Completed, University of Medicine and Pharmacy at Ho Chi Minh City
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PDO Thread Embedding Plus Binh Vi Tablets for Gastroesophageal Reflux Disease. Trials, record NCT07910656. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910656
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PDO Thread Embedding Plus Binh Vi Tablets for Gastroesophageal Reflux Disease
- NCT number
- NCT07910656
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 86 participants, actual
- Lead sponsor
- University of Medicine and Pharmacy at Ho Chi Minh City
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- PDO Thread Embedding, Esomeprazole 40 mg Oral Tablet, Binh Vi Tablets
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Gastroesophageal Reflux Disease Questionnaire (GerdQ) Score From Baseline to Week 4 | Baseline (T0) to week 4 (T4) | The GerdQ is a validated questionnaire used to assess the frequency of gastroesophageal reflux disease symptoms and their impact. The total score ranges from 0 to 18, with higher scores indicating more severe symptoms. The change in total GerdQ score from baseline to week 4 will be compared between the two study groups. |
| Secondary | Change in GerdQ Score From Baseline to Week 2 | Baseline (T0) to week 2 (T2) | The change in total GerdQ score from baseline to week 2 will be used to assess the short-term change in gastroesophageal reflux disease symptoms in both study groups. |
| Secondary | Clinical Response According to Traditional Medicine Criteria | Baseline (T0) to week 4 (T4) | Clinical response will be evaluated according to the traditional medicine criteria specified in the study protocol and compared between the two study groups. |
| Secondary | Change in EQ-5D-5L Quality-of-Life Scores From Baseline to Week 4 | Baseline (T0) to week 4 (T4) | Health-related quality of life will be assessed using the EQ-5D-5L questionnaire. Changes in the EQ-5D-5L scores from baseline to week 4 will be compared between the two study groups. |
| Secondary | Incidence of Adverse Events | From baseline (T0) through week 4 (T4) | The number and proportion of participants experiencing adverse events during the study will be recorded and compared between the two study groups. Adverse events associated with PDO thread embedding and other study interventions will be documented. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers10
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910656
GET https://conductscience.org/api/trials/v1/NCT07910656/registered